請更新您的瀏覽器

您使用的瀏覽器版本較舊,已不再受支援。建議您更新瀏覽器版本,以獲得最佳使用體驗。

Eng

Moleac Announces PT Ferron Par Pharmaceuticals as New Exclusive Partner in Indonesia

PR Newswire (美通社)

更新於 10小時前 • 發布於 11小時前 • PR Newswire

SINGAPORE, Oct. 21, 2024 /PRNewswire/ -- Moleac is excited to announce a significant milestone in the journey of NeuroAiD II MLC901 as PT Ferron Par Pharmaceuticals will become our exclusive partner in Indonesia effective Jan 1st 2025.

We are immensely grateful for the fruitful 12-year partnership with PT Mersifarma Tirmaku Mercusana, and we sincerely thank them for their invaluable contributions to our success in Indonesia. As we embark on a new chapter, we are thrilled to welcome PT Ferron Par Pharmaceuticals — a member of Dexa Group — as our new exclusive commercial partner.

This partnership marks a crucial milestone in our mission to widen access to our groundbreaking products, supporting healthcare professionals in enhancing outcomes for patients recovering from stroke, traumatic brain injuries, and neurodegenerative diseases.

With PT Ferron Par Pharmaceuticals, a leader renowned for its market expertise and operational excellence, we are confident in our accelerated growth and the expanded availability of NeuroAiD II MLC901 to those in need.

We look forward to a future of growth and continued innovation as we extend the reach of NeuroAiD II MLC901 in Indonesia to benefit more patients.

About Moleac

Moleac is a biopharmaceutical company that stays committed to helping patients and their families reconnect with their lives. We address unmet needs of patients suffering a loss of brain function after brain injuries or neurodegenerative diseases. Our focus is to help them regain and maintain independence. We select scientifically proven natural compounds and formulations with origins in traditional medicine, establish their clinical properties, and make them available internationally. For further information, visit moleac.com.

About PT Ferron Par Pharmaceuticals

PT Ferron Par Pharmaceuticals, a member of Dexa Group, is a fast growing pharmaceutical company that started its operation in 2001. Ferron has become one of the 20 largest pharmaceutical operations in Indonesia (Combined IHPA+IPA 2005, IMS Audit). With a diverse product portfolio, advanced manufacturing capabilities, and strong partnerships, Ferron continues to strengthen its market presence and operational excellence. For more information, visit dexagroup.com.

0 0
reaction icon 0
reaction icon 0
reaction icon 0
reaction icon 0
reaction icon 0
reaction icon 0

留言 0

沒有留言。